- Home
- Equipment
- usa massachusetts
- lung cell
Show results for
Refine by
Lung Cell Equipment Supplied In Usa Massachusetts
7 equipment items found
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS172738 is a highly selective, reversible, ATP-competitive RET (Rearranged during Transfection) kinase inhibitor. RET rearrangements and activating mutations are found in multiple solid tumors, but especially with non-small cell lung cancers and medullary thyroid carcinomas. ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Study lung physiology, disease, and the effect of drug candidates. A more human-relevant model for studying pulmonary physiology, with primary human cells in a lung-specific microenvironment. We are currently developing two distinct models of the human lung—the Alveolus Lung-Chip and the Airway ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during tumor growth.4 Mutations in the p53 protein lead to uncontrolled tumor progression and growth.4 Similar to Kristen ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. UpRi is being studied in UPLIFT, a single-arm registration ...
Manufactured by:Cellanyx, LLC based inBeverly, MASSACHUSETTS (USA)
Risk stratification of early-stage breast cancer is an active area of research and several commercially available products that are based on genotypic classification. A vexing issue in breast cancer is carcinoma in situ – which has no metastatic potential. There are two sub types – Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). The incidence of these entities is ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indication: PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). PEMFEXY is indicated as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous non-small cell ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most aggressive cancers. Preliminary data have shown that ELI-002 produces a potent mKRAS-specific T-cell response, including both CD4+ and CD8+ ...